Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses

Our results suggest that STING agonists may be able to work indirectly in MCC via signaling through immune and stromal cells in the TME, and may not necessarily need STING expression in the cancer cells. This approach may be particularly effective in tumors that are already infiltrated by inflammatory cells in the TME but are evading immune detection via HLA-I downregulation.

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2024-10-01
DOI
https://doi.org/10.1136/jitc-2024-009803
Citations
9
Primary Topic
Polyomavirus and related diseases
Type
article
Field-Weighted Citation Impact
2.54

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses

Saumya Jani, Shira Tabachnick‐Cherny, David M. Koelle, Candice D. Church et al.
9 citations
Journal for ImmunoTherapy of Cancer
Polyomavirus and related diseases
2.54
article

Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses

Saumya Jani, Shira Tabachnick‐Cherny, David M. Koelle, Candice D. Church, Kimberly S. Smythe, Brandon Seaton, Rima M. Kulikauskas, Shailender Bhatia, Rashmi Bhakuni, Thomas H. Pulliam, Peter H. Goff, Lisa Tachiki, Paul Nghiem
article en
9 citations

Abstract

Our results suggest that STING agonists may be able to work indirectly in MCC via signaling through immune and stromal cells in the TME, and may not necessarily need STING expression in the cancer cells. This approach may be particularly effective in tumors that are already infiltrated by inflammatory cells in the TME but are evading immune detection via HLA-I downregulation.

Journal for ImmunoTherapy of CancerVol. 12(10)
University of Washington (US), University of Washington Medical Center (US), Fred Hutch Cancer Center (US)
Bristol-Myers Squibb, Pfizer, Sanofi, Fred Hutchinson Cancer Research Center, University of Washington, Regeneron Pharmaceuticals, Incyte, Seagen, National Institutes of Health, EMD Serono, Sanofi Pasteur, National Cancer Institute, Office of Research Infrastructure Programs, National Institutes of Health
Good health and well-being
Openalex Percentile: Top 8%
Polyomavirus and related diseases
2.54
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.